Daniel Omstead - Tekla Life President
| HQL Stock | USD 14.13 0.02 0.14% |
President
Dr. Daniel R. Omstead Ph.D. is a President and Trustee of HQ Life Sciences Investors. Dr. Omstead is President and Chief Executive Officer of Tekla Capital Management LLC, a registered investment adviser that serves as investment adviser to HQH and HQL. Dr. Omstead is also President of HQH, HQL and THQ and serves on their Valuation Committee. Dr. Omstead is portfolio manager for the public and restrictedventure portfolios within HQH, HQL and THQ. As part of these responsibilities, Dr. Omstead is a member of the Board of Directors of several portfolio companies including IlluminOss Medical, Inc., Magellan Diagnostics, Inc., Dynex Corporationrationration, Insightra Medical, Inc., Neurovance, Inc., EBI Life Sciences, Inc. and Euthymics Biosciences, Inc. Dr. Omstead is also an observer of the Board of Directors of AlterG, Inc. Prior to joining the Adviser, Dr. Omstead was President and CEO of Reprogenesis, Inc., a private development stage biotech company which developed therapies in the field of tissue engineering and regenerative medicine. Before joining Reprogenesis, Dr. Omstead was Senior Vice President, Research and Development, at Cytotherapeutics, Inc, a public biotech company. Prior to entering the biotech industry, Dr. Omstead was employed for fourteen years in positions of increasing responsibility within the pharmaceutical industry at Ortho Pharmaceutical Corporation and at the R.W. Johnson Pharmaceutical Research Institute, both divisions of Johnson Johnson, and at Merck, Sharp and Dohme Research Laboratories, a division of Merck Co., Inc. Dr. Omstead provides each Fund with insights into both pharmaceutical and biotech companies since 2003.
| Age | 67 |
| Tenure | 22 years |
| Phone | 215 405 5700 |
| Web | https://www.teklacap.com/hql.html |
Daniel Omstead Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Omstead against Tekla Life stock is an integral part of due diligence when investing in Tekla Life. Daniel Omstead insider activity provides valuable insight into whether Tekla Life is net buyers or sellers over its current business cycle. Note, Tekla Life insiders must abide by specific rules, including filing SEC forms every time they buy or sell Tekla Life'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Omstead over six months ago Acquisition by Daniel Omstead of 5000 shares of Tekla Healthcare at 21.0108 subject to Rule 16b-3 | ||
Daniel Omstead over six months ago Acquisition by Daniel Omstead of 5950 shares of Tekla Life at 17.7489 subject to Rule 16b-3 | ||
Daniel Omstead over six months ago Disposition of 44064 shares by Daniel Omstead of Tekla Life at 19.75 subject to Rule 16b-3 | ||
Daniel Omstead over a year ago Purchase by Daniel Omstead of 10096 shares of Tekla Life |
Tekla Life Management Efficiency
Tekla Life's management efficiency ratios could be used to measure how well Tekla Life manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Chad Conwell | Flaherty and Crumrine | 47 | |
| Kevin McCarthy | Nuveen Preferred and | 55 | |
| Francis Gannon | Royce Value Closed | 52 | |
| Gifford Zimmerman | Nuveen California Select | 65 | |
| Maureen Gemma | Eaton Vance Tax | 61 | |
| Edward Perkin | Eaton Vance Tax | 49 | |
| Stephen Murphy | Cohen And Steers | 54 | |
| Christopher Rohrbacher | Nuveen California Select | 50 | |
| Maureen Gemma | Eaton Vance Risk | 61 | |
| Kevin McCarthy | Nuveen California Select | 55 | |
| Andrew Arnott | John Hancock Financial | 49 | |
| Nathaniel Jones | Nuveen California Select | 42 | |
| Yigal Jhirad | Cohen Steers Reit | 56 | |
| Jon Meissner | Nuveen Preferred and | 48 | |
| Joel Slager | Nuveen California Select | 41 | |
| Joseph Harvey | Cohen And Steers | 57 | |
| Chad Conwell | Flaherty Crumrine Preferred | 47 | |
| Bradford Stone | Flaherty and Crumrine | 60 | |
| Margo Cook | Nuveen California Select | 55 | |
| Walter Kelly | Nuveen Preferred and | 49 | |
| Tina Lazar | Nuveen Preferred and | 60 | |
Management Performance
| Return On Equity | 0.0128 | ||||
| Return On Asset | -0.0032 |
Tekla Life Sciences Leadership Team
Elected by the shareholders, the Tekla Life's board of directors comprises two types of representatives: Tekla Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tekla. The board's role is to monitor Tekla Life's management team and ensure that shareholders' interests are well served. Tekla Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tekla Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Thomas Kent, Independent Trustee | ||
| William Reardon, Independent Trustee | ||
| Elizabeth Nabel, Independent Trustee | ||
| Oleg Pohotsky, Independent Chairman of the Board of Trustees | ||
| Laura Woodward, Chief Compliance Officer, Treasurer, Secretary | ||
| Dr MS, President Officer | ||
| Peter Branner, Chief Officer | ||
| Lucinda Stebbins, Independent Trustee | ||
| Jeffrey Bailey, Independent Trustee | ||
| Daniel Omstead, Principal Executive Officer and President Trustee and Member of Valuation Committee | ||
| Rakesh Jain, Independent Trustee |
Tekla Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tekla Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0128 | ||||
| Return On Asset | -0.0032 | ||||
| Profit Margin | 1.56 % | ||||
| Operating Margin | (0.32) % | ||||
| Current Valuation | 370.8 M | ||||
| Shares Outstanding | 28.06 M | ||||
| Shares Owned By Insiders | 0.01 % | ||||
| Shares Owned By Institutions | 35.35 % | ||||
| Number Of Shares Shorted | 74.12 K | ||||
| Price To Earning | 2.84 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Tekla Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Asset Management & Custody Banks space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tekla Life. If investors know Tekla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tekla Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Tekla Life Sciences is measured differently than its book value, which is the value of Tekla that is recorded on the company's balance sheet. Investors also form their own opinion of Tekla Life's value that differs from its market value or its book value, called intrinsic value, which is Tekla Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tekla Life's market value can be influenced by many factors that don't directly affect Tekla Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tekla Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tekla Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tekla Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.